KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Total Debt (2018 - 2022)

TherapeuticsMD filings provide 8 years of Total Debt readings, the most recent being $93.6 million for Q3 2022.

  • On a quarterly basis, Total Debt fell 49.88% to $93.6 million in Q3 2022 year-over-year; TTM through Sep 2022 was $93.6 million, a 49.88% decrease, with the full-year FY2021 number at $188.3 million, down 20.79% from a year prior.
  • Total Debt hit $93.6 million in Q3 2022 for TherapeuticsMD, up from $90.8 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $243.8 million in Q2 2020 to a low of $73.1 million in Q2 2018.
  • Median Total Debt over the past 5 years was $187.5 million (2021), compared with a mean of $165.0 million.
  • Biggest five-year swings in Total Debt: soared 231.19% in 2020 and later crashed 51.0% in 2022.
  • TherapeuticsMD's Total Debt stood at $73.4 million in 2018, then surged by 165.24% to $194.6 million in 2019, then rose by 22.13% to $237.7 million in 2020, then dropped by 20.79% to $188.3 million in 2021, then crashed by 50.28% to $93.6 million in 2022.
  • The last three reported values for Total Debt were $93.6 million (Q3 2022), $90.8 million (Q2 2022), and $202.9 million (Q1 2022) per Business Quant data.